China’s poultry farming accounts for 50% of the world’s poultry population, with about 17 billion birds slaughtered annually. In the livestock and poultry farming industry, the prevention and control of epidemics is always a top priority. Avian influenza e la malattia di Newcastle are the “top killers” in the global poultry farming industry. Newcastle disease, as a serious threat to the health of poultry, has long brought substantial economic losses to farmers. The successful research and development of the Newcastle Disease Gene VII vaccine has forged a solid defense for the prevention and control of poultry disease and has become the dawn of the healthy development of the poultry farming industry.
With the continuous evolution of the Newcastle disease virus, the genotype VII strain has become the primary epidemic strain in recent years. It spreads fast and is highly pathogenic, and the control effect of traditional vaccines is not good. Once the poultry is infected with Newcastle disease, there will be dyspnea, diarrhea, neurological disorders, laying hens egg production decreasing significantly, young poultry mortality being very high, and so on, seriously affecting breeding efficiency. The Newcastle disease Genotype VII marker vaccine has been developed in response to this critical situation. The vaccine has excellent immunity against genotype VII Newcastle disease virus.
WIXBIO is collaborating with China’s most senior poultry research institute to launch the Newcastle disease Gene-VII marker inactivated vaccine. The vaccine has been licensed for sale in China and has received excellent customer feedback.
The technologies adopted in developing this vaccine:
1. Reverse Vaccinology technology platform
2.Homo-genotypic Vaccine
3. ND Negative Marker Vaccine and its accompanying diagnostic reagents
Highlights of the development of a marker vaccine for Newcastle disease:
- Le caratteristiche del vaccino sono: bassa tossicità, elevata efficienza, corrispondenza antigenica, stabilità genetica, marcatori unici e ottime prestazioni di crescita.
- Caratteristiche del vaccino: buona risposta immunitaria, ridotta eliminazione virale, elevata efficienza protettiva.
- Prodotti diagnostici di supporto: semplici, sensibili, ad alto rendimento, in grado di distinguere tra gli anticorpi sierici indotti dal ceppo vaccinale marcato della Malattia di Newcastle tipo VII e quelli indotti da altri ceppi della Malattia di Newcastle.
- Decontaminabile e valutabile: attraverso la soluzione tecnica è possibile bonificare le aree epidemiche interessate dal virus della Malattia di Newcastle, ridurre l'uso dei vaccini e dei farmaci veterinari correlati e abbattere i costi di allevamento.
Gli anticorpi prodotti dai polli SPF dopo l'immunizzazione con il vaccino inattivato marcato della Malattia di Newcastle tipo VII, utilizzando la dose minima e la dose immunizzante convenzionale, sono risultati superiori a quelli del gruppo La Sota.
Il tasso di rilevamento del vaccino inattivato marcato della Malattia di Newcastle tipo VII nell'escrezione virale è risultato inferiore a quello di La Sota.
Il tasso di rilevamento del virus ND negli organi del gruppo vaccinato con il vaccino inattivato marcato del gene VII della ND è risultato inferiore a quello del gruppo La Sota.
WIXBIO ha ottenuto il diritto di agenzia sul mercato internazionale per il Vaccino Inattivato Marcato Gene VII della Malattia di Newcastle e il diritto di promozione e vendita sul mercato internazionale della tecnologia di produzione del Vaccino Inattivato Marcato Gene VII della Malattia di Newcastle. WIXBIO è pronta a collaborare con i partner globali dei vaccini animali per prevenire e controllare le epidemie animali e per condividere prodotti per la protezione animale e soluzioni per le malattie della migliore qualità.
Le modalità di cooperazione sono le seguenti:
Agenzia esclusiva: WIXBIO signs an exclusive agency agreement with the distributor in the fixed distribution area. The distributor with the agency right is responsible for completing the registration of the Newcastle disease Gene-VII marked inactivated vaccine in its agent country and forming sales after obtaining the registration certificate.
Technical cooperation: This plan applies to animal vaccine manufacturers. After signing the agreement, the property owner of Newcastle Disease Gene-VII labeled inactivated vaccine production technology will provide training and guidance to the partners on all relevant technologies, such as research and development, production, and quality inspection of the vaccine until the partners produce qualified products.
Clean up the Newcastle disease virus and create an epidemic-free zone: All parties sign an agreement, give full play to the advantages of official policies, strive for the financial support of government projects, build an inter-governmental cooperation project, establish an epidemic-free zone or farm by using the vaccines and technical solutions of the property owner, and establish a standard of epidemic free zone or farm through WHO certification and local official certification.
Recent progress in the development of Newcastle disease type VII marker vaccine series:
- Creation of live attenuated marker vaccine for Newcastle Disease (ND) gene type VII.
- Research and development of inactivated inactivated gene VII marker vaccine for Newcastle Disease
- Application technology of Newcastle disease gene VII marker vaccine and other products in disease purification.
